Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice-Reference-Cited by-同舟云学术

Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice

Published:2018 Issue: Volume: Page:97-116
ISSN:0065-2598
Container-title:Advances in Experimental Medicine and Biology
language:
Short-container-title:

Author:

Masarova Lucia,Kantarjian Hagop,Ravandi Farhad,Sharma Padmanee,Garcia-Manero Guillermo,Daver Naval

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-030-02505-2_4

Reference65 articles.

1. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485–8.

2. Kantarjian HM. Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer. 2007;109:1007–10. https://doi.org/10.1002/cncr.22502 .

3. Saito Y, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra19. https://doi.org/10.1126/scitranslmed.3000349 .

4. Hauswirth AW, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest. 2007;37:73–82. https://doi.org/10.1111/j.1365-2362.2007.01746.x .

5. Larson RA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442–52. https://doi.org/10.1002/cncr.21326 .

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells;Biomedicines;2023-12-07

2. Advances in the pharmacological management of acute myeloid leukemia in adults;Expert Opinion on Pharmacotherapy;2022-09-02

3. Efficacy of 10-day decitabine in acute myeloid leukemia;Leukemia Research;2021-04

4. Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells;Experimental Hematology;2021-03

5. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy;Blood;2021-02-25